Jeb Keiper
InvestorFounderVenture Partner at Third Rock Ventures · Board director at Cardurion Pharmaceuticals, Inc.
East Coast
About
Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.
Invests in
BiotechHealthtechMedical Devices
Board director at Cardurion Pharmaceuticals, Inc.
Intro paths
→
In turn, Jeb can intro founders to Cardurion Pharmaceuticals, Inc.'s investors below.
Experience
- Third Rock VenturesVenture Partnercurrent2026 — presentBoston, Massachusetts, United States
- Strand TherapeuticsDirector Board of Directorscurrent2025 — presentBoston, Massachusetts, United States
- Cardurion PharmaceuticalsMember of the Boardcurrent2018 — presentCambridge, MA
- Nimbus TherapeuticsFormer Chief Executive Officer2025 — 2026
- Nimbus TherapeuticsCEO2018 — 2025Cambridge, MA
- Nimbus TherapeuticsChief Financial Officer2017 — 2018Cambridge, MA
- Nimbus TherapeuticsChief Business Officer2014 — 2018Cambridge, MA
- ROME TherapeuticsBoard Member2019 — 2026Cambridge, Massachusetts, United States
- GlaxoSmithKlineVP, Business Development, GSK Oncology2011 — 2014
- GlaxoSmithKlineHead, Acquisitions and Divestitures2009 — 2011
- GlaxoSmithKlineDirector, WW Business Development2008
- GlaxoSmithKlineDirector, R&D Executive Operations2005 — 2008
- McKinsey & Co.Engagement Manager2004 — 2005
- TransForm PharmaceuticalsBusiness Development Manager2003 — 2004
- Massachusetts General HospitalPharmacy Pharmacoeconomic Analyst2002 — 2003
- McKinsey & Co.Business Analyst2000 — 2002
- Mitsubishi Chemical CompanyEngineering Consultant2000
- PfizerScientist I, Pharmaceutical Sciences1998 — 1999
Education
- MIT Sloan School of ManagementMBA, Finance2002 — 2004
- Massachusetts Institute of TechnologyMS, Chemical Engineering1999 — 2000
- Massachusetts Institute of TechnologyBS, Chemistry1995 — 1998
Skills & more
Global Business Development3M&A experience2Venture Capital12Due Diligence11Mergers3Private Equity4Business Strategy8R&D15Oncology39Start-ups21Divestitures1Pharmaceuticals1
+12 more
BiotechnologyTechnology TransferFinancial ModelingLicensingValuationLife SciencesCompetitive IntelligenceEntrepreneurshipStrategic PlanningStrategy DevelopmentNegotiationStrategyLanguages German, broken
From Jeb's professional profile.
Deals · 2
Strand TherapeuticsBoard seat
via Third Rock Ventures · filed Mar 2026 · $120.1M raise
Cardurion Pharmaceuticals, Inc.Board seat
via Third Rock Ventures · filed Nov 2019 · $10M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Third Rock Ventures
Abbie Celniker
Investor at Third Rock Ventures
Adam Tebbe
Investor at Third Rock Ventures
Alan Ezekowitz
Investor at Third Rock Ventures
Alison Connors
Investor at Third Rock Ventures
Amanda Chan
Investor at Third Rock Ventures
Andrea van Elsas
Investor at Third Rock Ventures
Andrew Warren
Senior Associate at Third Rock Ventures
Angelo Severino
Investor at Third Rock Ventures
Frequently asked questions
- Who is Jeb Keiper?
- Jeb Keiper has over two decades in biotech leadership and strategic transactions. He was CEO of Nimbus Therapeutics from 2014 to 2025, where the company raised over $600 million and oversaw the zasocitinib deal with Takeda. He earlier held senior business development roles at GSK Oncology and worked at Pfizer, McKinsey, and TransForm Pharmaceuticals.
- Where does Jeb Keiper work?
- Jeb Keiper is Venture Partner at Third Rock Ventures and Board director at Cardurion Pharmaceuticals, Inc..
- What does Jeb Keiper invest in?
- Jeb Keiper invests in Biotech, Healthtech, Medical Devices.
- What boards does Jeb Keiper sit on?
- Jeb Keiper holds tracked board seats at Cardurion Pharmaceuticals, Inc., Strand Therapeutics.
- Where did Jeb Keiper go to school?
- Jeb Keiper studied at MIT Sloan School of Management (MBA, Finance); Massachusetts Institute of Technology (MS, Chemical Engineering); Massachusetts Institute of Technology (BS, Chemistry).
Same school
Also attended MIT Sloan School of Management490
Doug LeonePartner at Sequoia Capital; former Global Managing PartnerHemant TanejaCEO & Managing Director of General CatalystBrad FeldCo-founder of Foundry and TechstarsChris MorrisProcess Specialist, Exit Readiness at Mayfair Equity PartnersBirgitteInvestor at InvestinorOlaInvestor at Investinor
+ 484 more
Also attended Massachusetts Institute of Technology1,297
Fred WilsonCo-founder & Partner at Union Square VenturesElad GilSolo general partner investing through Gil CapitalAileen LeeFounder & Managing Partner of Cowboy VenturesHemant TanejaCEO & Managing Director of General CatalystNat FriedmanCo-lead of Meta Superintelligence Labs; co-founder of NFDGBrad FeldCo-founder of Foundry and Techstars
+ 1,291 more
Shared employers
Also worked at Cardurion Pharmaceuticals1
Also worked at Nimbus Therapeutics4
Also worked at GlaxoSmithKline111
Sam BlackmanEntrepreneur in Residence at GV (Google Ventures)Victoria TaylorInvestor at MedicxiJane SuhPrincipal on the AlleyCorp Healthcare teamCarol SuhPartner at ARCH Venture PartnersRudina SeseriFounder and Managing Partner at Glasswing VenturesDeb TraversEntrepreneur-In-Residence at The Innovation Space
+ 105 more
Also worked at McKinsey & Co.1,462
Elad GilSolo general partner investing through Gil CapitalJim BreyerFounder & CEO of Breyer CapitalAnn Miura-KoCo-founding Partner at FloodgateJeremy LiewPartner at Lightspeed Venture PartnersMike SpeiserManaging Director at Sutter Hill VenturesJeremy LevinePartner at Bessemer Venture Partners
+ 1,456 more